By Michael Smith, North American Correspondent, MedPage Today
Published: November 14, 2012
Reviewed by Robert Jasmer, MD; Associate Clinical Professor of Medicine, University of California, San Francisco
BOSTON – In a trial described by one expert as a “home run,” a combination of two investigational oral hepatitis C (HCV) medications delivered highly promising results.
But despite the excellent results, it’s unlikely the combination of daclatasvir and sofosbuvir will go forward – the drugs are owned by different pharmaceutical companies.
Interim results showed that the combination, with or without the standard HCV drug ribavirin, led to cure rates approaching 100%, according to Mark Sulkowski, MD, of Johns Hopkins University.
The combination appeared to yield similar results regardless of viral genotype or the presence of ribavirin, Sulkowski told a late-breaker session at the annual meeting here of the American Association for the Study of Liver Diseases.
“That’s a home run,” commented hepatologist Paul Pockros, MD, of Scripps Clinic in La Jolla, Calif., who was not involved in the study.
“The issue is they’re not likely to go forward,” he told MedPage Today.
Daclatasvir, an NS5A replication complex inhibitor, is owned by Bristol-Myers Squibb, while sofosbuvir, a nucleotide analog NS5B polymerase inhibitor, is being developed by Gilead Sciences.